Primary thrombocytopenic purpura is a disease of acquired thrombocytopenia, defined as peripheral platelets less than 100X109/L. The diagnosis requires the exclusion of other triggers or underlying diseases that cause thrombocytopenia, which is mostly immune-mediated. The pathogenesis of the disease is due to excessive destruction of autoantibody-sensitized platelets by the monocyte macrophage system. Cellular immune-mediated thrombocytopenia also plays an important role in the pathogenesis of the disease, as the immune dysregulation causes excessive platelet destruction and insufficient relative production, resulting in lower peripheral platelets and a series of bleeding symptoms, as follows: 1. Skin and mucous membrane damage: skin purpura, petechiae, petechiae, nose, gums and oral cavity mucosal bleeding, oral blood blisters; 2. Gastrointestinal bleeding: such as black stools and occasional vomiting of blood; 3. Urinary bleeding: such as hematuria; 4. Intracranial bleeding: manifested as headache, vomiting and other symptoms of intracranial hypertension, which can be life-threatening in severe cases. The treatment of this disease depends on the specific situation of the patient. Those with mild thrombocytopenia and no obvious bleeding tendency can be treated without special treatment; patients with severe bleeding tendency should be bedridden, avoid trauma, and avoid taking drugs that affect platelet function; glucocorticoids can be used for drug treatment, but attention should be paid to their side effects; splenectomy is also an effective method for treating this disease; for patients who cannot be relieved by the above methods For patients who cannot be relieved by the above methods, stem cell transplantation can be considered (please consult a specialist at a regular hospital for specific medications).